William Capo, MD
Cardiovascular Disease · Tampa, FLNPI 1356316822
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,810 of the $40,468 with a category attached, or 71.2%. 29 manufacturers reported payments, led by AstraZeneca at 53.4% of the total. Reporting peaked in 2020 at $11,033 and has fallen 88.5% since, to $1,273 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $116.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- Novartis$10K
- Abbott$2K
- Medtronic$842
- E.r. Squibb & Sons, L.L.C.$813
- Cvrx, Inc.$793
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$28,81071%
- Travel & lodging$100%
- Food & beverage$11,61529%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $21,592 |
| Novartis | 46 | $10,154 |
| Abbott | 57 | $2,039 |
| Medtronic(2 entities) | 15 | $842 |
| E.r. Squibb & Sons, L.L.C. | 27 | $813 |
| Cvrx, Inc. | 8 | $793 |
| Boehringer Ingelheim | 24 | $786 |
| Boston Scientific | 20 | $576 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $471 |
| Amgen | 16 | $425 |
| Pfizer | 16 | $375 |
| Edwards Lifesciences | 2 | $226 |
| Novo Nordisk | 5 | $204 |
| Atricure, Inc. | 2 | $197 |
| Heartflow, Inc. | 1 | $149 |
| Impulse Dynamics (USA) Inc. | 1 | $132 |
| Amarin Pharma, Inc. | 6 | $120 |
| Biotronik Inc. | 2 | $116 |
| Biosense Webster, Inc. | 1 | $103 |
| Bayer | 4 | $71 |
| Philips North America LLC | 3 | $63 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Siemens Medical Solutions USA, Inc. | 1 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Angiodynamics, Inc. | 1 | $27 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$20,814
- ENTRESTO$9,323
- Barostim Neo System$712
- CARDIOMEMS$489
- Reveal LINQ$418
- OPTIMIZER$265
- CAMZYOS$240
- JARDIANCE$239
- SAPIEN 3 Ultra RESILIA$178
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$173
- FFRct$149
- Farapulse$135
- Micra$128
- Ozempic$125
- RYBELSUS$125
- Repatha$124
- CardioMEMS HF System$121
- ELIQUIS$120
- Quadra Assura CRT Defibrillator$118
- Xience Sierra Coronary Stent System$114
How this compares
$40,468 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 399 | $346,173 |
| EntrestoSacubitril/Valsartan | 236 | $204,689 |
| FarxigaDapagliflozin Propanediol | 111 | $94,442 |
| JardianceEmpagliflozin | 71 | $49,343 |
| XareltoRivaroxaban | 29 | $34,885 |
| MultaqDronedarone Hcl | 15 | $21,590 |
| Repatha SureclickEvolocumab | 19 | $21,244 |
| Repatha SyringeEvolocumab | 29 | $15,671 |
| BrilintaTicagrelor | 22 | $11,710 |
| Metoprolol Succinate | 450 | $5,531 |
| Nitroglycerin | 135 | $3,378 |
| Ranolazine ErRanolazine | 38 | $2,956 |
| Potassium Chloride | 158 | $2,336 |
| Carvedilol | 296 | $1,932 |
| Propafenone Hcl | 13 | $1,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $375 | $346,173399 claims |
| NovartisEntresto | $10,154 | $204,689236 claims |
| AstraZenecaFarxiga, Brilinta | $21,592 | $106,151133 claims |
| Boehringer IngelheimJardiance | $786 | $49,34371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Tampa
- Hiram BezerraTampa$698K
- James SmithTampa$324K
- David WilsonTampa$258K
- Robby WuTampa$190K
- Jason FelibertiTampa$138K
- Samip VasaiwalaTampa$126K
- Kevin MakatiLutz$1.6M
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.